The ARAMIS randomized, double-blind, placebo-controlled phase 3 trial evaluated castration-resistant nonmetastatic prostate cancer patients with a PSA-specific doubling time of 10 months or less; the patients were assigned either to receive Darolutamide or placebo [203]. This evidence concerns the gene KLK3 and Familial prostate cancer.